|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:Japan
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:ATCCode
|
J05AX27
|
|
gptkbp:CASNumber
|
gptkb:142217-69-4
|
|
gptkbp:component
|
gptkb:Paxlovid
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredIn
|
2021
|
|
gptkbp:hasInChIKey
|
GGXKCSFZOLZJGS-GZNLMBLISA-N
|
|
gptkbp:hasMolecularFormula
|
C23H32N4O4
|
|
gptkbp:hasSMILES
|
CC(C)[C@@H](NC(=O)C1CCCN1C(=O)[C@H](NC(=O)CNC(=O)C2CCCO2)C3=CC=CC=C3)C(=O)N
|
|
gptkbp:hasTherapeuticUse
|
antiviral
|
|
gptkbp:hasUNII
|
QKJ1N59E5B
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
142217-69-4
|
|
gptkbp:IUPACName
|
N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(2S)-2-(4-morpholinylmethyl)-3,3-diphenylpropanoyl]-L-prolinamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
protease inhibitor
|
|
gptkbp:meltingPoint
|
~200°C (decomposes)
|
|
gptkbp:molecularWeight
|
499.53 g/mol
|
|
gptkbp:pregnancyCategory
|
Not assigned
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL4297599
gptkb:DB16335
155903259
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
hypertension
myalgia
dysgeusia
|
|
gptkbp:synonym
|
gptkb:Nirmatrelvir
|
|
gptkbp:target
|
gptkb:SARS-CoV-2_main_protease
|
|
gptkbp:usedFor
|
gptkb:COVID-19
|
|
gptkbp:bfsParent
|
gptkb:entecavir
|
|
gptkbp:bfsLayer
|
6
|